18:51:15 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-09-22 Kvartalsrapport 2023-Q2
2023-06-09 Årsstämma 2023
2023-04-21 Bokslutskommuniké 2022
2022-09-22 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriBioteknik
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.
2022-06-01 12:41:07
o	Real-time intravital imaging of the vascular effects induced by ACT® in a
murine brain

OSLO/LONDON, 1st June 2022: EXACT Therapeutics AS ("EXACT-Tx", Euronext Growth:
EXTX), a clinical-stage biopharmaceutical company with a mission to enhance the
therapeutic efficacy of medicines through ultrasound-mediated drug delivery,
today announces the presentation of preclinical results of Acoustic Cluster
Therapy (ACT®) in a murine brain model, at the Annual International Symposium
for Therapeutic Ultrasound (ISTU) Conference being held on 7th -10th June 2022
in Toronto, Canada.

The ISTU is a non-profit organization founded in 2001 to increase and diffuse
the knowledge of therapeutic ultrasound to the scientific and medical community
and facilitate the translation of therapeutic ultrasound techniques into the
clinical area for the benefit of patients worldwide.

The work presented by EXACT-Tx at the ISTU demonstrates the possibility of using
ACT® to help deliver therapeutics to the brain, addressing a significant unmet
medical need with close to 98% of drugs in development unable to cross the
blood-brain barrier (BBB).

Dr Masha Strømme, Executive Chair EXACT-Tx said: "These data sets have deepened
our understanding of the mechanism behind ACT®-induced increased BBB
permeability and enhanced accumulation of co-injected molecules, and also given
us new insights on the spatial and temporal extravasation pattern induced by
ACT®, important for understanding the mechanism of this therapeutic strategy for
drug delivery to the brain."

Presentation details are listed below:
Oral Presentation: Real-time intravital imaging of the vascular effects induced
by Acoustic Cluster Therapy (ACT®) in a murine brain
Session: Scientific Session 8A - Organ Focus: Brain.
Date and Time: Friday 10th June at 10.30am

ENDS
For more information, please contact:

Masha Strømme, Executive Chair
EXACT Therapeutics
Email: Masha@Exact-Tx.com

Dominic Moreland, CFO
EXACT Therapeutics
Email: Dominic@EXACT-tx.com

About EXACT-Tx
EXACT-Tx is a clinical-stage Norwegian precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101)
activated by ultrasound for enhanced drug targeting deployed in multiple
indications to enhance the therapeutic efficacy of medicines through the use of
ultrasound-mediated drug delivery, for patients across multiple diseases.
www.exact-tx.com

Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause Actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.